Ubs Group Ag Immuneering Corp Transaction History

Ubs Group Ag

$582 Billion
Q4 2025

A detailed history of Ubs Group Ag transactions in Immuneering Corp stock. As of the latest transaction made, Ubs Group Ag holds 190,333 shares of IMRX stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

190,333

Previous 126,402 50.58%

Holding current value

$1.22 Million

Previous $827,000 47.28%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2025 Jan 29, 2026	BUY	$5.35 - $6.91 $342,030 - $441,763	63,931 Added 50.58%	190,333 $1.22 Million
Q3 2025 Nov 13, 2025	BUY	$3.04 - $9.26 $368,840 - $1.12 Million	121,329 Added 2391.66%	126,402 $827,000
Q2 2025 Aug 14, 2025	SELL	$1.1 - $3.66 $25,825 - $85,929	-23,478 Reduced 82.23%	5,073 $17,000
Q1 2025 May 13, 2025	SELL	$1.46 - $2.36 $34,955 - $56,503	-23,942 Reduced 45.61%	28,551 $43,000
Q4 2024 Feb 14, 2025	BUY	$1.62 - $2.47 $33,935 - $51,741	20,948 Added 66.41%	52,493 $115,000

Q3 2024 Nov 14, 2024	BUY	$1.03 - $3.21 $25,226 - $78,619	24,492 Added 347.26%	31,545 $78,000
Q2 2024 Aug 13, 2024	SELL	$1.28 - $2.75 $28,029 - $60,219	-21,898 Reduced 75.64%	7,053 $9,000
Q1 2024 May 13, 2024	BUY	$1.91 - $7.32 $55,296 - $211,921	28,951 New	28,951 $83,000
Q1 2023 May 12, 2023	BUY	$3.78 - $10.38 $10,255 - $28,160	2,713 New	2,713 $26,000
Q3 2022 Nov 10, 2022	SELL	$5.0 - $14.32 $6,480 - $18,558	-1,296 Reduced 92.51%	105 $2,000
Q2 2022 Aug 10, 2022	SELL	$3.89 - $7.81 $7,243 - $14,542	-1,862 Reduced 57.06%	1,401 $8,000
Q1 2022 May 16, 2022	BUY	$6.47 - $16.99 $10,630 - $27,914	1,643 Added 101.42%	3,263 $21,000
Q4 2021 Feb 14, 2022	BUY	$16.12 - $31.02 $8,076 - $15,541	501 Added 44.77%	1,620 $26,000
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $19,023 - $36,747	1,119 New	1,119 $30,000

Others Institutions Holding IMRX

# of Institutions

Shares Held

14.5M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $169M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account